GT200200198A - Formas pseudopolimorficas de carvedilol - Google Patents

Formas pseudopolimorficas de carvedilol

Info

Publication number
GT200200198A
GT200200198A GT200200198A GT200200198A GT200200198A GT 200200198 A GT200200198 A GT 200200198A GT 200200198 A GT200200198 A GT 200200198A GT 200200198 A GT200200198 A GT 200200198A GT 200200198 A GT200200198 A GT 200200198A
Authority
GT
Guatemala
Prior art keywords
carvedilol
forms
pseudopolimorficas
pseudopolimorfic
betablocant
Prior art date
Application number
GT200200198A
Other languages
English (en)
Inventor
Andre Gerard Bubendorf
Rolf-Dieter Gabel
Michael Hennig
Siegfried Krimmer
Guenter Neugebauer
Walter Preis
Alexander Wirl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200198A publication Critical patent/GT200200198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMAS PSEUDOPOLIMORFICAS DE CARVEDILOL, ASI COMO SUS FORMAS OPTICAMENTE ACTIVAS O SALES FARMACEUTICAMENTE ACEPTABLES. EL CARVEDILOL ES UN BETABLOQUEANTE NO SELECTIVO CON UN AGENTE VASODILATADOR QUE ADEMAS PRESENTA PROPIEDADES ANTIOXIDANTES. EL OBJETIVO DEL INVENTO CONSISTE EN PROPORCIONAR UNA MEJORA EN LA CUOTA DE RESORCION DEL CARVEDILOL EN EL ORGANISMO, ESPECIALMENTE EN LAS REGIONES INFERIORES DEL INTESTINO, AL AUMENTAR LA SOLUBILIDAD Y/O VELOCIDAD DE DISOLUCION Y USANDO AGENTES DISPONIBLES EN LA TECNOLOGIA FARMACEUTICA.
GT200200198A 2001-09-28 2002-09-27 Formas pseudopolimorficas de carvedilol GT200200198A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123422 2001-09-28

Publications (1)

Publication Number Publication Date
GT200200198A true GT200200198A (es) 2003-06-19

Family

ID=8178782

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200198A GT200200198A (es) 2001-09-28 2002-09-27 Formas pseudopolimorficas de carvedilol

Country Status (20)

Country Link
US (3) US20030119893A1 (es)
EP (1) EP1432681B1 (es)
JP (1) JP2005507899A (es)
KR (1) KR100752549B1 (es)
CN (1) CN1308307C (es)
AR (1) AR036689A1 (es)
AT (1) ATE369339T1 (es)
AU (1) AU2002338726B2 (es)
BR (1) BR0212927A (es)
CA (1) CA2460486A1 (es)
DE (1) DE60221683T2 (es)
ES (1) ES2291503T3 (es)
GT (1) GT200200198A (es)
MX (1) MXPA04002826A (es)
PA (1) PA8555201A1 (es)
PE (1) PE20030448A1 (es)
PL (1) PL370412A1 (es)
RU (1) RU2308449C2 (es)
UY (1) UY27461A1 (es)
WO (1) WO2003029214A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
PL371409A1 (en) 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
KR20140006111A (ko) 2002-06-27 2014-01-15 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
SI21616A (sl) * 2003-09-02 2005-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Nove kristalne oblike karvedilola
KR20070088507A (ko) * 2005-06-09 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 카베딜올의 결정질 형태 및 이것의 제조 방법
WO2008002683A2 (en) * 2006-06-28 2008-01-03 Teva Pharmaceutical Industries Ltd. Polymorphous forms of carvedilol phosphate
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008105794A1 (en) * 2007-02-26 2008-09-04 Teva Pharmaceutical Industries Ltd. Process for the purification of carvedilol or its salts thereof
US20080249317A1 (en) * 2007-04-04 2008-10-09 Apotex Inc. Novel amorphous form of carvedilol phosphate and processes for the preparation thereof
TWI415604B (zh) 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
US20110229564A1 (en) * 2010-03-22 2011-09-22 Amneal Pharmaceuticals, L.L.C. Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3319027A1 (de) * 1983-05-26 1984-11-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung von optisch aktiven carbazol-derivaten, neue r- und s-carbazol-derivate, sowie arzneimittel, die diese verbindungen enthalten
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
EP0893440A1 (en) * 1997-07-22 1999-01-27 Roche Diagnostics GmbH Thermodynamically stable modification of 1-(4-carbazolyloxy)-3-[2-(2-methoxyphenoxy)ethylamino]-2-propanole, process for its preparation and pharmaceutical compositions containing it
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
CN1245974C (zh) * 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛

Also Published As

Publication number Publication date
AU2002338726B9 (en) 2003-04-14
AR036689A1 (es) 2004-09-29
PL370412A1 (en) 2005-05-30
BR0212927A (pt) 2004-10-13
MXPA04002826A (es) 2004-07-02
DE60221683T2 (de) 2008-04-30
UY27461A1 (es) 2003-06-30
WO2003029214A1 (en) 2003-04-10
PE20030448A1 (es) 2003-06-19
KR20040047872A (ko) 2004-06-05
CN1308307C (zh) 2007-04-04
DE60221683D1 (en) 2007-09-20
EP1432681A1 (en) 2004-06-30
US20030119893A1 (en) 2003-06-26
US20040198812A1 (en) 2004-10-07
RU2308449C2 (ru) 2007-10-20
KR100752549B1 (ko) 2007-08-30
PA8555201A1 (es) 2003-12-10
AU2002338726B2 (en) 2007-03-15
CN1558900A (zh) 2004-12-29
CA2460486A1 (en) 2003-04-10
JP2005507899A (ja) 2005-03-24
ATE369339T1 (de) 2007-08-15
ES2291503T3 (es) 2008-03-01
RU2004113209A (ru) 2005-05-20
US20060148878A1 (en) 2006-07-06
EP1432681B1 (en) 2007-08-08

Similar Documents

Publication Publication Date Title
GT200200198A (es) Formas pseudopolimorficas de carvedilol
HN2002000152A (es) Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco
AR111679A2 (es) Formulación farmacéutica de liberación controlada, procesos, usos, método
BR112015023391A2 (pt) formulações compreendendo conjugado droga-anticorpo anti-egfr
MA30765B1 (fr) Derives innovants du thiophene
ECSP088239A (es) Composición de liberación de fármaco sostenida
ECSP066670A (es) Prodroga florfenicol con mejor solubilidad en agua
PE20061015A1 (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
HN2001000266A (es) Agonistas selectivos del receptor ep4 en el tratamiento de la osteoporosis.
AR036302A1 (es) Asociacion de un antagonista del receptor cb1 con un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen, y su utilizacion en el tratamiento de la enfermedad de parkinson
CR8569A (es) Inhibidores de integrasa de vih
PE20040499A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
CL2020002252A1 (es) Formulación oftálmica.
MX2010005013A (es) Composiciones intranasales.
AR021639A1 (es) Marcas para lentes de contacto
ECSP099563A (es) Composiciones lubricantes personales complementarias
AR034200A1 (es) Agente para el cuidado de lentes de contacto, su uso, y procedimiento de limpieza
BR0012696A (pt) Composição oftálmica
AR065564A1 (es) Composiciones farmaceuticas que comprenden un agente calciletico
PE20130147A1 (es) Combinacion farmaceutica de teobromina y un agente antitusivo no opioide
BR0306629A (pt) Mancal articulado
PA8552301A1 (es) Metodo para el tratamiento de insomnio primario
CL2012001545A1 (es) Composiciones farmacéuticas acuosas que comprende un éster de un prostanoide, un ácido carboxílicoentre 1,2,1,6% de fosfato dibásico de sodio, cloruro de sodio, un agente de solubilización, y el resto de agua, con un ph va de 4 a 8; uso en desordenes oculares como glaucoma, retinopatia diabetica, uveitis, entre otras.
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
AR024769A1 (es) Composiciones abrasivas liquidas de limpieza